辅助双重生物疗法用于治疗多炎 (EGPA) 带有eosinophilic granulomatosis的持续性鼻腔症状
Giulia Gramellini1, Marco Borin1, Matteo Lazzeroni2
1Department of Otorhinolaryngology & Head and Neck Surgery, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
American journal of otolaryngology
|December 4, 2025
概括
双重生物疗法与dupilumab显示承诺与多炎 (EGPA) 患者经历持续的鼻腔症状,尽管抗IL-5/IL-5R的治疗. 这种方法改善了鼻腔结果,同时保持了全身缓解.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 耳鼻喉科 耳鼻喉科 耳鼻喉科
背景情况:
- 带有多炎 (EGPA) 的异性粒状炎是一种异性血管炎,通常与严重的喘和带有鼻息肉 (CRSwNP) 的慢性鼻炎有关.
- 虽然抗IL-5/IL-5R生物药物可以控制系统性EGPA,但有些患者患有耐火性鼻疾病.
研究的目的:
- 为了评估EGPA患者在抗IL-5/IL-5R治疗中持续性CRSwNP的补充dupilumab的疗效.
- 评估对鼻症状和全身疾病控制的影响.
主要方法:
- 关于两名耐火性CRSwNP的EGPA患者在抗IL-5/IL-5R治疗中的病例报告.
- 用dupilumab进行了补充治疗.
- 对鼻结局 (SNOT-22,聚得分) 和全身疾病活性 (BVAS) 进行了监测.
主要成果:
- 两位患者在鼻腔结局方面都经历了显著改善.
- 观察到SNOT-22和鼻息肉得分的减少.
- 在整个治疗过程中,全身缓解得到维持 (BVAS = 0).
结论:
- 补充dupilumab可能是EGPA耐火性CRSwNP患者的可行策略.
- 针对不同的炎症途径的双重生物疗法可以改善鼻结局.
- 需要进一步的研究来确认长期的疗效和安全性.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
COPD: Management Using Bronchodilators and Corticosteroids
705
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
705
Drugs Used in Lower Respiratory Disorders: Overview
1.0K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.0K


